Faran Muhammad, O'Callaghan Emma K, McKechnie Tyler, Barlow Karen, Kuszaj Olivia, Tarride Jean-Éric, Anvari Mehran, Doumouras Aristithes G
Centre for Surgical Invention and Innovation, Hamilton, Canada, ON.
McMaster University, Division of General Surgery, Hamilton, Canada, ON.
Obes Surg. 2025 Jul 25. doi: 10.1007/s11695-025-08054-6.
Glucagon-like peptide 1 (GLP-1) analogues are an emerging class of medications used to treat obesity. While studies show that postoperative liraglutide use is an effective adjunct treatment for patients with unsuccessful weight loss after bariatric surgery, the impact of preoperative liraglutide use on postoperative outcomes remains poorly understood. Therefore, the aim of this study was to determine if postoperative weight loss and comorbidity outcomes differ for patients who use liraglutide before their bariatric surgery.
Using data from the Ontario Bariatric Registry (OBR), we conducted a retrospective, matched cohort study of patients who underwent a primary bariatric procedure between January 2010 and June 2020. Liraglutide naive patients were matched with preoperative liraglutide users. The primary outcome of interest was percentage total body weight lost (TWL) from baseline to 1-year post-surgery.
A total of 1383 liraglutide naive patients were successfully matched to 449 liraglutide users at a ratio of 3:1. 1-year post-surgery; there were differences observed between groups in the primary outcome examined, with a higher TWL observed in the liraglutide naive group (27.52 ± 10.28% liraglutide naive vs. 25.46 ± 9.04% liraglutide users, p < 0.001).
While an increase in weight loss was observed in liraglutide naive patients, both groups had clinically significant weight loss and similar BMIs at 1-year post-surgery. This suggests that preoperative GLP-1 analogue users and GLP-1 analogue naive patients both benefit substantially from bariatric surgery.
胰高血糖素样肽1（GLP-1）类似物是一类新兴的用于治疗肥胖症的药物。虽然研究表明，术后使用利拉鲁肽是减肥手术后体重减轻未成功患者的一种有效辅助治疗方法，但术前使用利拉鲁肽对术后结果的影响仍知之甚少。因此，本研究的目的是确定减肥手术前使用利拉鲁肽的患者术后体重减轻和合并症结果是否存在差异。
利用安大略减肥登记处（OBR）的数据，我们对2010年1月至2020年6月期间接受初次减肥手术的患者进行了一项回顾性匹配队列研究。未使用过利拉鲁肽的患者与术前使用利拉鲁肽的患者进行匹配。主要关注的结果是从基线到术后1年全身体重减轻的百分比（TWL）。
共有1383名未使用过利拉鲁肽的患者以3:1的比例成功匹配到449名使用利拉鲁肽的患者。术后1年；在检查的主要结果中观察到两组之间存在差异，未使用利拉鲁肽的组观察到更高的TWL（未使用利拉鲁肽组为27.52±10.28%，使用利拉鲁肽组为25.46±9.04%，p<0.001）。
虽然未使用过利拉鲁肽的患者体重减轻有所增加，但两组在术后1年都有临床上显著的体重减轻和相似的体重指数。这表明术前使用GLP-1类似物的患者和未使用GLP-1类似物的患者都从减肥手术中获益匪浅。
